Sign Up for Our E-Newsletter

“Would I jinx myself if I adopted the title survivor?”

Posted on June 1, 2017

Every story – like cancer itself – is unique. This blog is part of our ongoing 2017 Survivor Week. Join us from May 29-June 4 as we unpack the complexity of what it means to be a cancer survivor, from those who reject the word entirely to individuals who have embraced their diagnosis with a new sense of purpose. What does being a survivor mean to you?

This post was written by Dawn Eicher, a stage IV survivor at only age 36. Read more

“Being a survivor is all about attitude.”

Posted on May 29, 2017

Every story – like cancer itself – is unique. This blog is part of our ongoing 2017 Survivor Week. Join us from May 29-June 4 as we unpack the complexity of what it means to be a cancer survivor, from those who reject the word entirely to individuals who have embraced their diagnosis with a new sense of purpose. What does being a survivor mean to you?

This post was written by Vanessa Ghigliotty, a stage IV survivor at age 28. Read more

“Survivorship begins from the moment you are diagnosed.”

Posted on May 26, 2017

Every story – like cancer itself – is unique. This blog is part of our ongoing 2017 Survivor Week. Join us from May 29-June 4 as we unpack the complexity of what it means to be a cancer survivor, from those who reject the word entirely to individuals who have embraced their diagnosis with a new sense of purpose. What does being a survivor mean to you?

This post was written by Valarie Schlosser, a stage IV survivor at age 49. Read more

Statement from Colon Cancer Alliance CEO Michael Sapienza on AHCA assessment by the CBO

Posted on May 24, 2017

Today the Congressional Budget Office (CBO) provided an assessment of what will happen if the American Health Care Act (AHCA) becomes law. The synopsis provides negative foreshadowing, especially in the cancer community, with statistics including: 51 million Americans will be uninsured by 2026, a dramatic increase in out-of-pocket healthcare costs, and a steep decrease in access to life-saving treatments and care. Read more

UPDATED as of 5/24/17: Keytruda Approved for MSI-H Colorectal Cancer Patients

Posted on May 23, 2017

Merck’s Keytruda has just been approved by the FDA for patients with a microsatellite instability-high (also known as MSI-H) or a mismatch repair deficient (dMMR) biomarker following progression on a fluoropyrimidine, oxaliplatin, and irinotecan. This marks an unprecedented step for the FDA, as it is the first time they have approved a cancer drug based on genetics rather than tumor location.

The FDA approval of Merck’s Keytruda is a game changer for both our colorectal cancer community as well as the cancer community at-large,” said Michael Sapienza, Colon Cancer Alliance CEO. “While the results from Keytruda’s recent clinical trial are incredibly promising, the biggest victory here is that this approval sets a precedent for expedited approval for other new drugs across the genetic spectrum. For every cancer patient, time is of the utmost importance. In the future, colorectal cancer patients could get faster access to treatments working for breast or lung cancer.”

Read more

css.php